



EXPRESS MAIL NO. EV336654895US

PTO/SB/01A (08-03).

Approved for use through 10/31/2002. OMB 0651-0032.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****Title of Invention****COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/728,738, filed on December 4, 2003,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)Inventor one: Andreas H. SarrisCitizen of: United StatesSignature: Andreas H SarrisDate: 14 May 2004Inventor two: Fernando CabanillasCitizen of: United StatesSignature: F.C. CabanillasDate: 6/9/04 June 9, 2004Inventor three: Patricia M. LoganCitizen of: CanadaSignature: P. LoganDate: June 17, 2004Inventor four: Clive T.R. BurgeCitizen of: CanadaSignature: Clive T.R. BurgeDate: 26 April 2004X Additional inventors or a legal representative are being named on One additional form(s) attached hereto.



This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 480208.401C2

V471112_1.DOC

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five:	<u>James H. Goldie</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u>April 28 2004</u>
Inventor six:	<u>Murray S. Webb</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u>3 May, 2004</u>
Inventor seven:	<u></u>	Citizen of:	<u></u>
Signature:	<u></u>	Date:	<u></u>
Inventor eight:	<u></u>	Citizen of:	<u></u>
Signature:	<u></u>	Date:	<u></u>

☐ Additional inventors or a legal representative are being named on ____ additional form(s) attached hereto.

ASSIGNMENT

WHEREAS, we, Andreas H. Sarris and Fernando Cabanillas (hereinafter referred to as ASSIGNORS), having mailing addresses of 35 Tsaldari Street, 14561 Kifissia, Athens, Greece and Condominio Milenio, 550 Ponce de Leon, Apt. 1202, San Juan, Puerto Rico, 00901, respectively, along with Patricia M. Logan, Clive T.R. Burge, James H. Goldie and Murray S. Webb are the joint inventors of an invention entitled "COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA," as described and claimed in the specification forming part of a continuation-in-part application for United States letters patent which was filed on December 4, 2003 and assigned Application No. 10/728,738; this application is a continuation-in-part of U.S. Application No. 09/541,436, filed March 31, 2000, which application claims the benefit of U.S. Provisional Application Nos. 60/137,194, filed June 2, 1999 and 60/127,444, filed April 1, 1999;

WHEREAS, Board of Regents, The University of Texas System (hereinafter referred to as ASSIGNEE), a university of the State of Texas having a place of business at 201 West 7th Street, Suite 820, Austin, TX 78701, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Applicants' counsel is authorized to insert the official filing date and application number information when it becomes available.

14 May 2004
Date
Andreas H. Sarris
Andreas H. Sarris
City of Athens)
County of Attica) ss.
Country of Greece)

6/9/04 June 9, 2004
Date
C. L. S. /
Fernando Cabanillas
City of SAN JUAN)
County of PUERTO RICO) ss.
Country of U.S.A.)

ASSIGNMENT

WHEREAS, we, Patricia M. Logan, Clive T.R. Burge, James H. Goldie and Murray S. Webb (hereinafter referred to as ASSIGNORS), having mailing addresses of 2738 West 10th Avenue, Vancouver, B.C., CANADA V6K 2J9, 917 Dalmert Way, Brentwood Bay, B.C., CANADA V8M 1C2, 2558 West 7th Avenue, Vancouver, B.C., CANADA V6K 1Y9, and 3640 Sunnycrest Drive, North Vancouver, B.C., CANADA V7R 3C6, respectively, along with Andreas H. Sarris and Fernando Cabanillas are the joint inventors of an invention entitled "COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA," as described and claimed in the specification forming part of a continuation-in-part application for United States letters patent which was filed on December 4, 2003 and assigned Application No. 10/728,738; this application is a continuation-in-part of U.S. Application No. 09/541,436, filed March 31, 2000, which application claims the benefit of U.S. Provisional Application Nos. 60/137,194, filed June 2, 1999 and 60/127,444, filed April 1, 1999;

WHEREAS, INEX Pharmaceuticals Corporation (hereinafter referred to as ASSIGNEE), a Canadian corporation having a place of business at 100-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, B.C., CANADA V5J 5J8, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters

patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Applicants' counsel is authorized to insert the official filing date and application number information when it becomes available.

June 17, 2004
Date

City of Vancouver)

Province of British Columbia)

Patricia M. Logan
Patricia M. Logan

ss.

26 April - 2004
Date

City of Burnaby)

Province of British Columbia)

Clive T.R. Burge
Clive T.R. Burge

ss.

April 28 2004
Date

City of Vancouver)

Province of British Columbia)

James H. Goldie
James H. Goldie

ss.

3 May, 2004
Date

City of N. Vancouver)

Province of British Columbia)


Murray S. Webb

ss.

**ELECTION AND POWER OF
ATTORNEY and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/728,738
Filing Date	December 4, 2003
First Named Inventor	Andreas H. Sarris
Title	COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA
Art Unit	1615
Examiner Name	
Attorney Docket Number	480208.401C2

I hereby appoint:

☒ Practitioners at Seed IP Law Group PLLC, Customer Number: **00500**

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR


<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country					
Telephone		Fax			

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ As assignee of record of the entire interest I/we hereby elect, under 37 CFR 3.71, to prosecute the application to the exclusion of the inventor(s).**SIGNATURE of Applicant or Assignee of Record**

Name	David J. Main - President & CEO
Signature	
Date	June 23/04

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Andreas H. Sarris et al.Application No./Patent No.: 10/728,738 Filed/Issue Date: December 4, 2003Entitled: COMPOSITIONS AND METHODS FOR TREATING LYMPHOMAINEX Pharmaceuticals Corporation

(Name of Assignee)

a

corporation(Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____%

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above.
The assignment was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the
current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title noted in B above are
attached.**[NOTE:]** A separate copy (i.e., the original assignment document or a true copy of the original document) must be
submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records
of the USPTO. See MPEP 302.8]


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 23/04
Date604-419-3200

Telephone Number

David J. Main

Typed or printed name


SignaturePresident & CEO

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Andreas H. Sarris et al.Application No./Patent No.: 10/728,738 Filed/Issue Date: December 4, 2003Entitled: COMPOSITIONS AND METHODS FOR TREATING LYMPHOMABoard of Regents, The University of Texas a university
System
(Name of Assignee)(Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____%

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above.
The assignment was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the
current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title noted in B above are
attached.**[NOTE:** A separate copy (i.e., the original assignment document or a true copy of the original document) must be
submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records
of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 30, 2004


Date

512/499-4462

Telephone Number

Cullen M. Godfrey


Typed or printed name




Signature

Vice Chancellor and General Counsel

Title





EXPRESS MAIL NO. EV336654895US

PTO/SB/81 (06-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ELECTION AND POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/728,738
	Filing Date	December 4, 2003
	First Named Inventor	Andreas H. Sarris
	Title	COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA
	Art Unit	1615
	Examiner Name	
	Attorney Docket Number	480208.401C2

I hereby appoint:

☒ Practitioners at Seed IP Law Group PLLC, Customer Number: **00500**

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country					
Telephone		Fax			

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ As assignee of record of the entire interest I/we hereby elect, under 37 CFR 3.71, to prosecute the application to the exclusion of the inventor(s).**SIGNATURE of Applicant or Assignee of Record**

Name	Cullen M. Godfrey - Vice Chancellor and General Counsel
Signature	
Date	June 30, 2004

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

VOHNO471133_1.DOC